A Multicenter Phase 2 Open-Label, Single-Arm, Prospective, Interventional Study of Plasma-Derived Factor VIIIIVWF Alphanate in Immune Tolerance Induction Therapy in Subjects with Congenital Hemophilia A.

Trial Profile

A Multicenter Phase 2 Open-Label, Single-Arm, Prospective, Interventional Study of Plasma-Derived Factor VIIIIVWF Alphanate in Immune Tolerance Induction Therapy in Subjects with Congenital Hemophilia A.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Oct 2017

At a glance

  • Drugs Factor VIII/von Willebrand factor (Primary)
  • Indications Haemophilia A
  • Focus Therapeutic Use
  • Sponsors Grifols
  • Most Recent Events

    • 12 Sep 2017 Planned initiation date changed from 1 Jun 2017 to 1 Sep 2017.
    • 04 Aug 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top